Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Figure 8
(A) Immunostaining of glucagon (green), BrdU (yellow), and DAPI (blue) in pancreas sections from BrdU-terated non-diabetic control mice and diabetic mice with restored normoglycemia after 7 weeks treatment with PSN632408, sitagliptin, or PSN632408 combined with sitagliptin.
White arrows indicate glucagon/BrdU/DAPI co-positive cells. (B) The percentage of glucagon/BrdU/DAPI co-positive cells among total glucagon positive cells was significantly increased in mice treated with PSN632408 and sitagliptin combination compared with mice treated with PSN632408 alone or sitagliptin alone (p<0.05, n = 3 to 5 mice per group). (C) Immunostaining of amylase (green), BrdU (red), and DAPI (blue) in pancreas sections from BrdU-treated non-diabetic control mice and diabetic mice with restored normoglycemia after 7 weeks treatment with PSN632408, sitagliptin, or PSN632408 combined with sitagliptin.